Huang Bo-Hao, Guo Zi-Wei, Lv Bo-Han, Zhao Xin, Li Yan-Bo, Lv Wen-Liang
Department of Infection, Guang'an Men Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Graduate school, Beijing University of Chinese Medicine, Beijing, China.
Front Pharmacol. 2024 May 24;15:1396834. doi: 10.3389/fphar.2024.1396834. eCollection 2024.
This meta-analysis aimed to determine the efficacy of curcumin in preventing liver fibrosis in animal models.
A systematic search was conducted on studies published from establishment to November 2023 in PubMed, Web of Science, Embase, Cochrane Library, and other databases. The methodological quality was assessed using Sycle's RoB tool. An analysis of sensitivity and subgroups were performed when high heterogeneity was observed. A funnel plot was used to assess publication bias.
This meta-analysis included 24 studies involving 440 animals with methodological quality scores ranging from 4 to 6. The results demonstrated that curcumin treatment significantly improved Aspartate aminotransferase (AST) [standard mean difference (SMD) = -3.90, 95% confidence interval (CI) (-4.96, -2.83), < 0.01, I = 85.9%], Alanine aminotransferase (ALT)[SMD = - 4.40, 95% CI (-5.40, -3.40), < 0.01, I = 81.2%]. Sensitivity analysis of AST and ALT confirmed the stability and reliability of the results obtained. However, the funnel plot exhibited asymmetry. Subgroup analysis based on species and animal models revealed statistically significant differences among subgroups. Furthermore, curcumin therapy improved fibrosis degree, oxidative stress level, inflammation level, and liver synthesis function in animal models of liver fibrosis.
Curcumin intervention not only mitigates liver fibrosis but also enhances liver function, while concurrently modulating inflammatory responses and antioxidant capacity in animal models. This result provided a strong basis for further large-scale animal studies as well as clinical trials in humans in the future. https://www.crd.york.ac.uk/prospero/, identifier CRD42024502671.
本荟萃分析旨在确定姜黄素在动物模型中预防肝纤维化的疗效。
对PubMed、科学网、Embase、Cochrane图书馆及其他数据库中从建库至2023年11月发表的研究进行系统检索。使用Sycle的RoB工具评估方法学质量。当观察到高度异质性时，进行敏感性分析和亚组分析。采用漏斗图评估发表偏倚。
本荟萃分析纳入24项研究，涉及440只动物，方法学质量评分在4至6分之间。结果表明，姜黄素治疗显著改善了天冬氨酸转氨酶（AST）[标准均数差（SMD）=-3.90，95%置信区间（CI）（-4.96，-2.83），P<0.01，I²=85.9%]、丙氨酸转氨酶（ALT）[SMD=-4.40，95%CI（-5.40，-3.40），P<0.01，I²=81.2%]。AST和ALT的敏感性分析证实了所得结果的稳定性和可靠性。然而，漏斗图显示不对称。基于物种和动物模型的亚组分析显示亚组间存在统计学显著差异。此外，姜黄素治疗改善了肝纤维化动物模型的纤维化程度、氧化应激水平、炎症水平和肝脏合成功能。
姜黄素干预不仅可减轻肝纤维化，还可增强肝功能，同时调节动物模型中的炎症反应和抗氧化能力。这一结果为未来进一步的大规模动物研究以及人体临床试验提供了有力依据。https://www.crd.york.ac.uk/prospero/，标识符CRD42024502671。
